HEART UK Statements of Care

As a specialist charity in cholesterol conditions and other blood fat conditions, the HEART UK Medical, Scientific and Research Committee have produced Statements of Care to help inform best practice

We would like to thank everyone involved for their time and dedication to improving the lives of patients.

Current management of children and young people with heterozygous FH

This consensus statement includes lifestyle and dietary advice suitable for children, suggested LDL cholesterol targets, and the most appropriate lipid-lowering therapies.

Management of homozygous FH in the UK

This consensus statement addresses the three main treatments for HoFH: pharmacotherapy, lipoprotein apheresis and liver transplantation.

Consensus statement on Lipoprotein (a): a call to action

High Lp(a) is an independent risk factor for CVD. This consensus statement includes the ten most important points for understanding, measuring and treating high Lpa.

Managing hyperlipidaemia in patients with COVID-19

This expert panel position statement from HEART UK aims to collate current evidence surrounding the safety of lipid-lowering medications in patients who have COVID-19.

Our COVID-19 statement explained

Watch Dr Handrean Soran presenting the COVID statement at our 2020 Virtual Lipid Update

Find other relevant guidelines and policies

Go

See our information on cholesterol and COVID-19

Go